Results 171 to 180 of about 113,609 (263)
Diagnosis and Management of Prenatal Hereditary Pyropoikilocytosis
ABSTRACT Hereditary pyropoikilocytosis (HPP) is a severe hemolytic anemia caused by variants in SPTA1, SPTB, and EPB41. These weaken horizontal interactions in the erythrocyte cytoskeleton, causing membrane fragmentation and splenic sequestration. It will readily cause fetal anemia and often hydrops fetalis. Prenatal diagnosis requires first ruling out
Connor Hartzell +6 more
wiley +1 more source
Chimeric Antigen Receptor T-Cell Revolution Remodeling Immunity to Conquer Autoimmune Disease. [PDF]
Shao W, Liu J, Sun M, Yu D.
europepmc +1 more source
Single‐center retrospective data showed that ATG‐based myeloablative haploidentical hematopoietic stem cell transplantation provides durable remission and favorable long‐term survival in children with refractory/relapsed non‐Hodgkin lymphoma, achieving high engraftment rates, low relapse incidence, and acceptable toxicity.
Chenguang Jia +12 more
wiley +1 more source
CD19-Negative Acute Lymphoblastic Leukemia (ALL): A Case Report and Review of Literature on a Rare Phenomenon De Novo and a Future Induced Struggle in Relapse. [PDF]
Arrabito M +4 more
europepmc +1 more source
ABSTRACT Withania somnifera (L.) Dunal (WS), commonly known as Ashwagandha, is a prominent medicinal herb in Ayurveda, with extensive therapeutic potential attributed to its diverse phytochemical profile. This review critically examines the immunomodulatory properties of WS, focusing on innate immune cell populations, including neutrophils, eosinophils,
Rana Yukta +9 more
wiley +1 more source
Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses. [PDF]
Zhang K +11 more
europepmc +1 more source
This large‐scale retrospective study of 5778 primary Sjögren's disease (SjD) patients, stratified by diagnostic age, defines a distinct clinical and immunological profile for early‐diagnosed (<45 years) disease. We identified early diagnosis as an independent risk factor for hypergammaglobulinemia and interstitial lung disease, underpinned by a ...
Yuan Ning +7 more
wiley +1 more source
Lust H, Schultz LM, Kwon S, et al. Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv. 2025;9(11):2763-2772. [PDF]
europepmc +1 more source
Beyond malignancies: Clinical advancements of CAR T-cell in the treatment of autoimmune diseases. [PDF]
Fang X, Wei R, Zhu W, Hu Y, Liang H.
europepmc +1 more source

